Please assess the completion status of the following clinical trial:

Trial Title: Alendronate Versus Denosumab in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult ≥ 18 year old and medically stable.~* Recent kidney transplantation (up to 3 months).~* Stabilization of renal allograft function.~* Normal liver function.~* Reduced bone mineral density at least one SD lower than normal level for the same age and gender (T-score \< -1).~Exclusion Criteria:~* Poor or unstable graft function (creatinine \>200 lmol/L).~* Skeletal malignancies or bone metastases.~* Risk for osteosarcoma, such as Paget's disease of the bone.~* Unstable medical condition.~* Pregnancy and lactation.~* Autoimmune diseases.~* Predisposition to drug hypersensitivity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): Participants will receive daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
- Denosumab group (Type: EXPERIMENTAL): Participants will receive a single 60 mg subcutaneous dose of denosumab (Prolia) every 6 months for 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).
- Alendronate group (Type: EXPERIMENTAL): Participants will receive an oral alendronate at a dose of 70 mg once every week for up to 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).

Based on this trial design, predict the completion outcome and termination type (if applicable).